The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.

[1]  P. Fauchald,et al.  Hydralazine slow-release: observations on serum profile and clinical efficacy in man. , 1977, Current therapeutic research, clinical and experimental.

[2]  S. Hunyor,et al.  Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype. , 1975, Australian and New Zealand journal of medicine.

[3]  R. Zacest,et al.  Relation of hydralazine plasma concentration to dosage and hypotensive action , 1972, Clinical pharmacology and therapeutics.

[4]  A. Glazko,et al.  The polymorphic acetylation of dapsone in man , 1971, Clinical pharmacology and therapeutics.